2015 BPD Header

Cambridge Healthtech Institute’s 4th Annual
High-Concentration Protein Formulations:
Formulation, Manufacturing, Analytics, High Viscosity, Aggregation, Devices and Delivery
August 5-6, 2015
Part of CHI's 7th Annual The Bioprocessing Summit

August 3-7, 2015 | Westin Copley Place Hotel | Boston, Massachusetts


At higher concentrations, proteins or antibodies exhibit characteristic problems including aggregation, precipitation, gelation, and increased viscosity. Development of these high-concentration protein formulations results in several manufacturing, stability, analytical, and delivery challenges. The popular High-Concentration Protein Formulations conference will feature informative, high quality case studies and successful strategies to overcome the problems you are facing with development and delivery of high-concentration formulations. We invite you to attend to learn from and network with the leading experts from around the world.


Day 1 | Day 2 | Short Courses | Download Brochure 


Tuesday, August 4


6:00-8:30 Recommended Dinner Short Course

Protein Aggregation: Mechanism, Characterization and Consequences 


Wednesday, August 5

7:00 am Registration and Morning Coffee


PROTEIN-PROTEIN INTERACTIONS & DEALING WITH VISCOSITY

8:05 Chairperson’s Remarks

Bruce Kerwin, Ph.D., Head, Drug Product Design, Just Biotherapeutics, Inc.


KEYNOTE PRESENTATION:
8:15 Protein-Protein Solvation in High-Concentration Solutions

Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire

At high concentrations, proteins will distribute themselves in a manner that minimizes the system free energy. Mechanistically, this means that proteins will form an increasingly important component of the solvation shell around any given protein. The importance of considering protein-protein solvation for both single-protein solutions, as well as for mixtures of proteins, will be described, and experimental data showing these effects will be presented.

9:00 Viscosity in High-Concentration Protein Formulations

Thomas Palm, Ph.D., Senior Research Investigator II, Drug Product Science and Technology, Bristol-Myers Squibb Co.

At high protein concentration, small changes in concentration or pH that are within the typical specification range can have a significant impact on product viscosity. Likewise, product viscosity is significantly higher at storage temperature of 2-8 °C than it is at ambient temperature. Viscosity ranges of a model antibody and implications for formulation development, manufacturing, and device development will be discussed.

9:30 Cluster Formation in Dense Protein Solutions and Its Implications to Solution Viscosity

Yun Liu, Ph.D., Research Associate Professor/Instrument Scientist, Chemical & Bimolecular Engineering/Center for Neutron Research, University of Delaware/National Institute of Standards and Technology

Protein cluster formation in solutions is of fundamental interest for both academics and industries, and is very important for solution viscosity control in concentrated protein solutions. We will present our recent research efforts to directly identify the structures of small reversible protein clusters in monoclonal antibody solutions. The fundamental physical mechanisms of high viscosity in monoclonal protein solutions will be discussed within the context of our research examples.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing


FORMULATION & CMC CHALLENGES OF HIGH-CONCENTRATION PROTEIN FORMULATIONS

10:45 Preformulation Screening for Risk Mitigation during the Development of Biopharmaceuticals

Randall Mauldin, Ph.D., Scientist II, Protein Formulation and Process Development, Biogen Idec

In order to address unmet patient needs, drug candidates are becoming more complex and delivered at higher concentration than ever before. Furthermore, aggressive CMC timelines necessitate the need for a rigorous assessment of early-stage drug candidates to de-risk future development. This talk will provide an overview of the challenges and strategies for characterizing the multidimensional formulation space of novel biopharmaceuticals with limited sample availability.

11:15 HESylation® - A Versatile Polymer Modification Technology Enabling High-Concentration Protein Formulations

Thomas Hey, Ph.D., Director, Biochemistry, Innovation Center Complex Formulations, Fresenius Kabi Deutschland GmbH

The attachment of the biodegradable and poorly immunogenic polymer hydroxyethyl starch (HES) to biologicals leads to increased efficacy by stabilization of the protein and prevention of renal excretion. The resulting conjugates show high solubility, but comparably low viscosity, allowing s.c. administration of highly concentrated solutions. In addition, HESylation® was used to develop next-generation ADCs allowing site-specific conjugation and higher payload density while maintaining excellent binding activity with the target protein and cancer cells.

TerumoBCT11:45 Sponsored Presentation

Kevin Constable, Director, Technology Development, Terumo- Global Pharmaceutical Solutions

 
12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:30 Session Break


FORMULATION & CMC CHALLENGES OF HIGH-CONCENTRATION PROTEIN FORMULATIONS (cont.)

1:55 Chairperson’s Remarks

Thomas Palm, Ph.D., Senior Research Investigator II, Drug Product Science and Technology, Bristol-Myers Squibb Co.

2:00 Drug Product Design and High Concentration Formulation Development

Bruce Kerwin, Ph.D., Head, Drug Product Design, Just Biotherapeutics, Inc.

Protein formulation development is an evolving field that now encompasses the concept of drug product design rather than focusing solely on stabilization and concentration of the protein. Increasingly, an integrated approach to drug product design encompasses in silico tools, high throughput screening and development of predictive tools that integrate with the commercialization process. At this meeting examples and ideas will be combined to provide a vision of the future as it evolves into the field of drug product design.

2:30 CMC Strategies on Scaling Up and Down for High-Concentration Protein Formulations

Jamie Tsung, Ph.D., Principal Scientist, Momenta Pharmaceuticals, Inc.

Highly concentrated therapeutic proteins are prone to be viscous and aggregate posing developmental and CMC challenges in purification, formulation, analytical development, manufacturing, product stability, syringeability and injectability. This talk provides a review of current strategies and technologies used in product development to overcome these CMC challenges and minimize the impact on product quality.

3:00 Aromatic Amino Acid Salts Rescue the Solubility of a Poorly Soluble Multivalent Protein

Yu Tang, Ph.D, Principal Scientist, Integrated Biologics Profiling, Novartis

A multivalent protein demonstrates poorly solubility across wide pH range with temperature dependency. Conventional “salt in” ions further facilitate the precipitation of the protein. Interestingly, aromatic amino acid salts successfully rescue the protein solubility. A systemic investigation was performed to reveal the cause of the poor solubility and the mechanism of solubility enhancement by aromatic amino acid salts.

3:30 Breakout Discussions

This session provides the opportunity to discuss a focused topic with peers from around the world in an open, collegial setting. Select from the list of topics available and join the moderated discussion to share ideas, gain insights, establish collaborations or commiserate about persistent challenges. Then continue the discussion as you head into the lively exhibit hall for information about the latest technologies.

4:00 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Plenary Keynote Session (see page 2 for details)

6:00 Networking Reception in the Exhibit Hall with Poster Viewing

7:00 End of Day


Day 1 | Day 2 | Short Courses | Download Brochure 


Thursday, August 6

8:00 am Registration and Morning Coffee


ANALYTICAL STRATEGY FOR HIGH-CONCENTRATION PROTEIN FORMULATIONS

8:25 Chairperson’s Remarks

Jan Jezek, Ph.D., CSO, Development, Arecor Ltd.

8:30 Building a Better Bridge: Biophysical Tools to Better Understand the Complexities of High Concentration Biotherapeutics

Michael S. Marlow, Ph.D., Senior Staff Scientist, Protein Biochemistry, Regeneron Pharmaceuticals, Inc.

The thermodynamic interactions that govern a variety of protein therapeutic and solution properties are distinctly protein concentration dependent. Manufacturing and dosing of therapeutic monoclonal antibodies frequently calls for high protein concentration solutions and the resulting non-ideality complicates reliable estimation of critical properties from measurements under dilute conditions. We illustrate the utility of different biophysical tools in bridging the dilute - high concentration gap by characterizing two antibodies that exhibit contrasting concentration-dependent behavior.

9:00 Challenges with Measuring Detergents and Excipients Used in Biopharmaceuticals

Shiranthi Jayawickreme, Ph.D., Associate Director, Analytical Development, Biogen Idec

A variety of detergents are used for solubilization, viral-inactivation, and as excipients in Biopharmaceutical drug substances and products. Lack of chromaphores in many of these detergents poses a challenge for the detection and quantitation of these components during process development and quality control. Current methods available for the determination of low levels of polysorbates in high concentration drug substances and drug products will be presented. Sensitivity and robustness of three different methods will be discussed.

9:30 Characterization of and Relationship between Soluble and Insoluble Aggregate Populations

Ronald Maurer, Ph.D., Scientist, Process Development – Downstream, Bristol-Myers Squibb Co.

Protein aggregation presents serious challenges in all stages of biotherapeutic development, compromising both product yield and patient safety. However, many fundamental aspects of aggregation are poorly described and prevent robust characterization and prediction of aggregation behavior. In this work, we investigate the relationship, if any, between soluble and insoluble protein particle formation and correlate their growth and stability to experimentally-tenable biophysical properties.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing


DELIVERY & DEVICE APPROACHES IN HIGH-CONCENTRATION / HIGH-VOLUME PROTEIN FORMULATIONS

10:45 Device & Formulation – Two Inseparable Aspects of a Successful Product

Jan Jezek, Ph.D., CSO, Development, Arecor Ltd.

The biologics market is becoming increasingly competitive with multiple products competing for the same indication and a number of biosimilars in development. Therefore, there is a strong pressure for product differentiation offering distinct advantages over other products. Stability together with a convenient injection device are two key aspects of successful products. This talk will focus on unique formulation strategies and related device choices that enable development of competitive biopharmaceuticals.

11:15 Reconstitution of Highly Concentrated, Dried Proteins: What Have We Learned in the Past 5 Years?

Bakul Bhatnagar, Ph.D., Principal Scientist, Formulation & Process Development, Pfizer, Inc.

The reconstitution time of lyophilized biopharmaceuticals is a quality attribute where it is desirable and often critical to achieve fast reconstitution (for example, in an emergency environment) without compromising the product quality. The reconstitution times of highly concentrated freeze-dried proteins can be often quite long. The presentation will address recent advances in our understanding of the dissolution behavior and will cover aspects of mechanisms contributing to reconstitution, strategies to obtain rapid reconstitution, and methods to determine the end of reconstitution.

11:45 Adocia Viscosity Reducers (AVRs®) – A New Alternative to Reduce the Viscosity of Highly Concentrated mAb Formulations

Emmanuel Dauty, Ph.D., Head of the Physico-Chemistry Department, Department: Physico-Chemistry, Adocia

Highly concentrated monoclonal antibody (mAb) formulations are often highly viscous, which poses manufacturing and administration challenges. Adocia has developed two distinct families of small molecules that have impressive viscosity-reduction properties in highly concentrated mAb formulations – Adocia Viscosity Reducers (AVR®). Through low-affinity electrostatic and hydrophobic interactions, AVR® excipients are capable of disrupting the mAb-mAb interaction network responsible for the high viscosity of highly-concentrated mabs, resulting in significant viscosity reduction.

12:15 pm Sponsored Presentation (Opportunity Available)

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Close of Conference


Day 1 | Day 2 | Short Courses | Download Brochure